12:46 - 30.10.2026

---

October 30, Fineko/abc.az. AstraZeneca plans to invest $2 billion in restructuring, expecting to save $1.5 billion annually. The funds will be used to develop new drugs.

The company is expanding cooperation with Summit Therapeutics and Dizal Pharmaceutical in the field of oncology. Trials of the combination of Imfinzi and tarlatamab showed a 58% reduction in the risk of death from lung cancer, but a number of other studies were discontinued or did not achieve their goals.

AstraZeneca's net debt has increased by $2.46 billion since the beginning of the year, up to $25.83 billion. The company also intends to appeal several court decisions.

The 2026 dividend is to be increased up to $3.30 per share.